Pain Clinical Trial
— MT-MW-EXOfficial title:
Effectiveness of Magnetotherapy and Microwaves Combined With Therapeutic Exercise in Patients With Knee Osteoarthritis.
Verified date | May 2021 |
Source | University of Castilla-La Mancha |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The high prevalence of knee osteoarthritis and the absence of well-defined protocols for the application of Magnetotherapy (MT), makes it necessary to investigate the effect of this therapy on patients with knee osteoarthritis. Furthermore, no studies are comparing the effectiveness of the two interventions proposed in this project (MT) and microwaves (MW), which are routinely applied in clinical practice, without solid scientific evidence to justify their use. The purpose of the present clinical trial is to compare MT with MW both combined with a therapeutic exercise program in patients with painful knee osteoarthritis and its influence on pain and function.
Status | Completed |
Enrollment | 60 |
Est. completion date | July 25, 2023 |
Est. primary completion date | January 26, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 85 Years |
Eligibility | Inclusion Criteria: - Patients older than 45 years old - Unilateral or bilateral knee osteoarthritis. - Kellgren and Lawrence (K-L) grade II or III. - Visual analog scale (VAS) greater than 40mm. - Affectation of more than one year of evolution. - Sign and understand the informed consent form. Exclusion Criteria: - Secondary cause osteoarthritis - History of uncontrolled metabolic diseases. - Decompensated or uncontrolled pathologies - Tumor processes. - Collagenopathies and neurological diseases. - Changes in medication or invasive treatments at least 1 month prior to treatment. - Receiving physiotherapy treatment or having received it one month prior to the start of the osteoarthritis study. - Patients with alterations in thermal sensitivity. - Pacemaker - Skin alterations (recent wounds or burns). - Knee prosthesis - Thrombophlebitis |
Country | Name | City | State |
---|---|---|---|
Spain | Juan Avendaño Coy | Talavera De La Reina | Toledo |
Lead Sponsor | Collaborator |
---|---|
University of Castilla-La Mancha | Centro de Salud Talavera Centro y Centro de Salud La Algodonera., Clínica Radiodiagnóstico Marazuela, Empresa Helios Electromedicina S.L. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in knee pain | The knee pain perceived in motion and at rest will be measured with the standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. Being the value 0 "no pain" and the value 10 "worst pain". | Change from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Primary | Change in function | Physical function, pain, and stiffness will be measured with the Western Ontario and McMaster Universities Arthritis Index (WOMAC-24). It is a self-administered questionnaire consisting of 24 items divided into 3 subscales. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. | Change from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Primary | Daily knee pain | The daily level of knee pain will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst functionality. | Before each treatment session. 3 sessions per week (total 4 weeks) | |
Primary | Daily level of functionality | The level of functionality will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst functionality. | Before each treatment session (during 4 weeks) | |
Primary | Daily quality of sleep | The quality of sleep will be measured before every session of treatment using a standard 10 cm Visual Analog Scale (VAS). It will be expressed in mm. The value 0 will be the best and 10 the worst. | Before each treatment session (during 4 weeks) | |
Primary | Daily intake of oral non-opioid analgesic medication | Daily intake of oral non-opioid analgesic medication (number of pills per day) during the 24 hours interval before each treatment session being the value 0 the best and 10 the worst. | Before each treatment session (during 4 weeks) | |
Primary | Change in balance and fall risk | Test timed up and go (TUG) will be expressed in seconds. It uses the time that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down. The test will be performed 3 times. The mean of the three tests will be used. Less time performing this test indicates better mobility. | Mean differences from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Secondary | Change in patient quality of life | The European Quality of life 5 Dimensions (EuroQoL 5D-5L) is a questionnaire that evaluates the generic quality of life measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each health state is usually represented using a 5-digit number (profile) where 11111 indicates perfect health and 55555 the worst health state. | Index change from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Secondary | Change in lower limb strength | Maximal isometrical knee extension and flexion strength will be measure with a hand dynamometer and will be expressed in Kgs. The researcher will perform three measurements and the final result will be the average of the three. | Mean difference from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Secondary | Blinding assesment | The success of participant and assessor blinding will be evaluated through a questionnaire after each intervention with five questions: (1) "Strongly believe the applied intervention is new treatment"; (2) "Somewhat believe the applied intervention is new treatment"; (3) "Somewhat believe the applied intervention is a placebo", (4) "Strongly believe the applied intervention is a placebo", or (5) "Do not know". | Post treatment at 4 weeks | |
Secondary | Number of participants with adverse effects | The number of participants who suffered adverse effects will be reported by the researcher (for example skin erythema, rush, or itching...). | Post each treatment session (during 4 weeks) | |
Secondary | Change in knee range of motion | Knee active and passive range of motion will be measure with the WERIUM sensors. It will be expressed in degrees. The mean of 3 movements of flexion and extension will be calculated. | Mean difference from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Secondary | Change in perceived generic health status | The European Quality of life 5 Dimensions (EuroQoL 5D-5L) questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status). | Change from baseline at 4 weeks, 1 month and 4 months after intervention. | |
Secondary | Doses of analgesic and antidepressant medication | The doses of analgesic and antidepressant medication will be recorded at baseline.
Taking into account the therapeutic steps of the World Health Organization and the dosage, 4 values will be established concerning the basal state: "increases, decreases, it is eliminated or it is maintained". |
Change from baseline at 4 weeks. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|